Table 1 |
|||||||
|
Summary of intake data by receptor status and antioestrogenic drug prescription |
|||||||
|
Total phytoestrogen intake (μg/1,000 kcal) (n = 316) |
n |
First quartile |
Second quartile |
Third quartile |
Fourth quartile |
||
|
|
|||||||
|
Receptor status |
|||||||
|
Mean |
8,388 |
ER-negative |
42 |
11 (14%) |
11 (14%) |
13 (16%) |
7 (9%) |
|
Range |
126 to 77,703 |
ER-positive |
182 |
40 (51%) |
42 (53%) |
48 (61%) |
52 (66%) |
|
Quartile ranges |
Not available |
92 |
28 (35%) |
26 (33%) |
18 (23%) |
20 (25%) |
|
|
First quartile |
<3,817 |
Antioestrogenic drugs |
|||||
|
Second quartile |
3,817 to 6,798 |
No prescription |
109 |
30 (38%) |
30 (38%) |
25(32%) |
24 (30%) |
|
Third quartile |
6,799 to 10,255 |
Tamoxifen or arimidexa |
200 |
47 (59%) |
47 (59%) |
52 (65%) |
54 (68%) |
|
Fourth quartile |
>10,255 |
Other/missing |
7 |
2 (3%) |
2 (3%) |
2 (3%) |
1 (2%) |
|
|
|||||||
|
aAstraZeneca, London, UK. |
|||||||
|
Parry et al. Breast Cancer Research 2008 10(Suppl 2):P92 doi:10.1186/bcr1976 |
|||||||